Revach OY, et coll. showed the importance of CD38 as new additional player in CD8 defense restauration in melanoma PDX ex vivo.
Read this oustsanding work in Cell Rep Med. 2025 Jun 27;6(7):102210
CD38 as a Therapeutic Target in Melanoma
CD38 is upregulated in exhausted CD8⁺ T cells in melanoma
Associated with resistance to immune checkpoint blockade (ICB)
Induced by chronic TCR stimulation and type I interferon signaling
Disrupting CD38 restores:
NAD⁺ levels
Mitochondrial function
T cell effector activity
Dual blockade (PD-1 + CD38) enhances response in ICB-resistant PDXmodels
This supports clinical evaluation of CD38-targeted therapies